US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Q/C TECHNOLOGIES INC,

4.39

-1.1100-20.18%

Post-market: 4.530.1392+3.17%19:59 EDT

Volume:1.39M

Turnover:6.55M

Market Cap:8.11M

PE:-0.01

High:5.53

Open:5.53

Low:4.20

Close:5.50

52wk High:189.00

52wk Low:3.24

Shares:1.85M

Float Shares:1.85M

Volume Ratio:1.12

T/O Rate:75.42%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-558.7158

EPS(LYR):-1,114.5350

ROE:-115.40%

ROA:-24.00%

PB:1.58

PE(LYR):0.00

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Q/C TECHNOLOGIES INC,

Exchange:

NASDAQ

Establishment Date:

2014

Employees:

6

Office Location:

1185 Avenue of the Americas,Suite 249,New York,New York,United States

Website:

http://www.tnfpharma.com

Zip Code:

10036

Phone:

Fax:

- -

Introduction:

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Directors

Name

Position

Joshua Silverman

Executive Chairman

Mitchell Glass

Director and Chief Medical Officer

Bill J. White

Director

Bruce Bernstein

Director

Christopher C. Schreiber

Director

Stephen Friscia

Director

Shareholders

Name

Position

Ian Rhodes

Interim Chief Financial Officer

Joshua Silverman

Executive Chairman

Mitchell Glass

Director and Chief Medical Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/QCLS/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"QCLS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QCLS\",,,,,undefined,":{"symbol":"QCLS","market":"US","secType":"STK","nameCN":"Q/C TECHNOLOGIES INC,","latestPrice":4.39,"timestamp":1760731200000,"preClose":5.5,"halted":0,"volume":1393021,"hourTrading":{"tag":"盘后","latestPrice":4.5292,"preClose":4.39,"latestTime":"19:59 EDT","volume":12506,"amount":55558.7354,"timestamp":1760745594385},"delay":0,"floatShares":1846930,"shares":1846930,"eps":-558.7158,"marketStatus":"Market Closed","change":-1.11,"latestTime":"10-17 16:00:00 EDT","open":5.53,"high":5.53,"low":4.1968,"amount":6547814.415282,"amplitude":0.2424,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-558.7158,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"listingDate":1390453200000,"exchange":"NASDAQ","adjPreClose":5.5,"preHourTrading":{"tag":"盘前","latestPrice":5.4701,"preClose":5.5,"latestTime":"09:29 EDT","volume":87192,"amount":474682.664736,"timestamp":1760707760115},"postHourTrading":{"tag":"盘后","latestPrice":4.5292,"preClose":4.39,"latestTime":"19:59 EDT","volume":12506,"amount":55558.7354,"timestamp":1760745594385},"volumeRatio":1.120131081468402},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QCLS\",,,,,undefined,":{"symbol":"QCLS","floatShares":1846930,"roa":"-24.00%","roe":"-115.40%","lyrEps":-1114.535,"volumeRatio":1.120131081468402,"shares":1846930,"dividePrice":0,"high":5.53,"amplitude":0.2424,"preClose":5.5,"low":4.1968,"week52Low":3.24,"pbRate":"1.58","week52High":189,"institutionHeld":0,"latestPrice":4.39,"eps":-558.7158,"divideRate":0,"volume":1393021,"delay":0,"ttmEps":-558.7158,"open":5.53,"prevYearClose":115,"prevWeekClose":3.68,"prevMonthClose":4.15,"prevQuarterClose":4.15,"fiveDayClose":3.68,"twentyDayClose":3.86,"sixtyDayClose":13.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/QCLS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-09-02","symbol":"QCLS","defaultRemindTime":1756819800000,"type":"split","dateTimestamp":1756785600000,"forFactor":100,"toFactor":1,"ratio":100},{"market":"US","date":"2025-08-19","symbol":"QCLS","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755576000000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-02-15","symbol":"QCLS","defaultRemindTime":1708007400000,"type":"split","dateTimestamp":1707973200000,"forFactor":30,"toFactor":1,"ratio":30},{"market":"US","date":"2023-11-14","symbol":"QCLS","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":-0.11},{"market":"US","date":"2023-08-14","symbol":"QCLS","fiscalQuarterEnding":"2023/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1691985600000,"reportTimeType":"post","actualEps":-0.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"QCLS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"QCLS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/QCLS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"QCLS","date":"2025-10-17","current":-0.007857,"percent":0,"low":-2.368501,"twenty":-1.335871,"median":-1.113652,"eighty":-1.036514,"high":-0.939963,"avg":-1.270555,"sd":0.393211,"marketCap":16377196},"quantilePoints":[{"date":"2025-10-03","current":-1.302666,"twenty":-1.20867,"median":-1.072784,"eighty":-1.056437,"marketCap":9007395},{"date":"2025-10-10","current":-1.014036,"twenty":-1.261798,"median":-1.107266,"eighty":-1.056437,"marketCap":7011639},{"date":"2025-10-17","current":-2.368501,"twenty":-1.335871,"median":-1.113652,"eighty":-1.036514,"marketCap":16377196}],"updateTime":1760836584754},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":694917951,"yearFounded":2014,"employeeNum":6,"address":"1185 Avenue of the Americas,Suite 249,New York,New York,United States","zipCode":"10036","officePhone":"856 848 8698"},"stockCompanyDetail":{"websiteUrl":"http://www.tnfpharma.com","stockEarnings":[{"period":"1week","weight":0.1929},{"period":"1month","weight":0.1344},{"period":"3month","weight":-0.4983},{"period":"6month","weight":-0.7604},{"period":"1year","weight":-0.9752},{"period":"ytd","weight":-0.9618}],"compareEarnings":[{"period":"1week","weight":0.0174},{"period":"1month","weight":0.0079},{"period":"3month","weight":0.0587},{"period":"6month","weight":0.2621},{"period":"1year","weight":0.1409},{"period":"ytd","weight":0.1336}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":0.11774},{"month":2,"riseRate":0.416667,"avgChangeRate":0.081589},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.004232},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.072762},{"month":5,"riseRate":0.25,"avgChangeRate":-0.070295},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.011804},{"month":7,"riseRate":0.25,"avgChangeRate":0.033577},{"month":8,"riseRate":0.25,"avgChangeRate":-0.156511},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.048614},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.009327},{"month":11,"riseRate":0.090909,"avgChangeRate":-0.255267},{"month":12,"riseRate":0.181818,"avgChangeRate":-0.213952}],"exchange":"NASDAQ","name":"Q/C TECHNOLOGIES INC,","nameEN":"Q/C TECHNOLOGIES INC,"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"QCLS\",market:\"US\",,,undefined,":{"directors":[{"name":"Joshua Silverman","position":"Executive Chairman"},{"name":"Mitchell Glass","position":"Director and Chief Medical Officer"},{"name":"Bill J. White","position":"Director"},{"name":"Bruce Bernstein","position":"Director"},{"name":"Christopher C. Schreiber","position":"Director"},{"name":"Stephen Friscia","position":"Director"}],"executives":[{"name":"Ian Rhodes","position":"Interim Chief Financial Officer"},{"name":"Joshua Silverman","position":"Executive Chairman"},{"name":"Mitchell Glass","position":"Director and Chief Medical Officer"}]}}}